Latest News about EXEL
Recent news which mentions EXEL
From Benzinga
From Benzinga
Exelixis-BioInvent Establish Immuno-Oncology Pact
June 16, 2022
From Benzinga
From Motley Fool
From InvestorPlace
From Benzinga
From Motley Fool
From Benzinga
3 Growth Stocks to Buy With $1,000 Right Now
May 03, 2022
From Motley Fool
From Benzinga
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
May 03, 2022
From Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
April 21, 2022
From InvestorPlace
Nasdaq Bear Market: 3 of the Safest Stocks to Buy on the Dip
April 13, 2022
From Motley Fool
From Motley Fool
2 Stocks Defying the Market Sell-Off Right Now
March 29, 2022
From Motley Fool
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
March 25, 2022
From Benzinga
From Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
From Benzinga
3 Stocks That Can Turn $10,000 Into $50,000 by 2025
March 11, 2022
From Motley Fool
2 Biotech Stocks That Could Make You Richer
March 02, 2022
From Motley Fool
3 Surefire Stocks to Buy Hand Over Fist During the Stock Market Sell-Off
February 25, 2022
From Motley Fool
Earnings Scheduled For February 17, 2022
February 17, 2022
From Benzinga
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial
February 15, 2022
From Benzinga
2 Biotech Stocks That Could Make You Richer
February 02, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.